R&B Bio Raises RMB 200 Million in Series A+ Round to Advance Gene Therapy Pipeline
Chengdu-based gene therapy firm R&B Biotech has reportedly secured over RMB 200 million (USD 29.64...
Chengdu-based gene therapy firm R&B Biotech has reportedly secured over RMB 200 million (USD 29.64...
South Korea-based Daewoong Pharmaceutical has entered into an exclusive licensing agreement with UK-based CS Pharmaceuticals...
China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the renewal of a supply,...
Enkang Pharmaceutical Technology (Guangzhou) Co., Ltd, a developer of DNA replication-initiation proteins (DRIPs)-targeted drugs, has...
China-based CAR-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced a clinical cooperation...
China-based Contract Research Organization (CRO) Tigermed (SHE: 300347, HKG: 3347) has announced the completion of...
China-based RemeGen Ltd (HKG: 9995) and Allist Pharmaceuticals Inc. (SHA: 688578) have announced a clinical...
Akeso Inc. (HKG: 9926) has announced receiving the first installment of USD 300 million as...
Shenzhen Yinghe Brain Science Co., Ltd, a China-based neurotechnology firm, has reportedly raised over RMB...
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced a licensing deal with Japanese...
Tianjin-based biotech Protein T, focused on multi-omics research, has reportedly raised close to RMB 100...
Guangdong-based antibody drug developer Dartsbio Pharmaceuticals has reportedly raised over RMB 100 million in a...
Suzhou-based Ascentage Pharma (HKG: 6855) is set to conduct a secondary offering of 22.5 million...
Contract Development and Manufacturing Organization (CDMO) GenScript ProBio has announced the completion of a $220...
Swiss pharmaceutical giant Roche (SWX: ROG) has signed a multi-faceted collaboration agreement with the Hong...
US-based Pasithea Therapeutics Corp. (NASDAQ: KTTA) has announced that Chinese Contract Research Organization (CRO) WuXi...
Jiangsu-based MDHC Life Technologies (Kunshan) Co.,Ltd, a leading platform in minimally invasive surgery and life...
Hangzhou-based oncology-focused clinical-stage biotech Bliss Bio has reportedly raised over RMB 100 million (USD 14.7...
Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced the termination of a licensing deal...
Structure Therapeutics Inc. (Nasdaq: GPCR), a Sino-US firm formerly known as ShouTi Inc., has filed...